Yes, absolutely. So just to start, I would like to acknowledge that this paper is funded, and it has been like, produced in collaboration with the IEO, which is the European Institute for Oncology based in Milan, and Ethox, of course, where I'm studying, I'm doing my PhD at the moment, and together with also colleagues from four different European countries. So we had many colleagues that help us in doing this amazing work. And yeah, the paper is very big empirical work that we did, trying to tackle the data infrastructure that manage the health-related data collected during the pandemic, and the findings and what we trying to give to the public and well, basically based on, tackle the challenges and the opportunities that we can, that they emerge from the new European Health Data Space regulation. That is a regulation that has been approved by the European Commission in 2024 and we try to yes, tackle these challenges and opportunities. So in just like very few words, we'll be trying to tackle was the data access procedure and the data access mechanism that is very different between all these state infrastructure in these four different European countries. Namely, they are United Kingdom, which, I mean, is a bit controversial because it's not exactly in the European Union anymore, but is jointly and is strictly related to both the European Health Data Space and also because of geographical reason, and we have Italy and we have Denmark and Sweden. So the yeah, first of all, we have this very diverse data access procedure across all the European countries. And then, of course, we trying to tackle, now that the status quo is that different data access provision for corporate actors across countries, most of the data infrastructure are embedded in singularities and in their context. Okay, so, and the European Health Data Space is basically strive to standardise the procedure across all the countries. So this might disappear at some point. And of course, there's like at the status quo, a lack of ethics oversight in some countries, and this was something that we will we were able to see during the pandemic, especially. So tackling the COVID-19 data and, yeah, so these are, like the challenges and the status quo we're trying to map. And of course, the opportunities that the European Health Data Space in some way try to offer us is to, of course, streamline the access to the health data in Europe and the access of them. And then, of course, they, they try to facilitate the international access to all the singular health data in different countries by a variety of actors. So basically, the European Health Data Space is trying to give the opportunity to access all these data, right, in a kind of free way, in both, both like economically, and without, of course, all the data access barriers. But there are some challenges due to the status quo. So basically, since we have all this fragmentation in different countries because of the procedure that are now in place. For example, we, the European data space needs to restructure and reorganise completely the governance of the health data in Europe, and this can be costly and administratively very complex and well, of course, we don't also know how they they envisage to put all together different type of data that needs to be standardised at some point. So there are also technological challenges, so technical and technological challenges. If we think about the context where these infrastructure grows, of course, we might see some loss of local expertise and contextual expertise, because some of the infrastructure have been built in ages, and in those countries, they know how to collect the data, how to also establish the mechanism of collecting these data, so this might be lost at some point. And for the last point, the one that, of course, provide the access to different type of actors, such as Big Tech companies or private companies. Of course, these can be a challenge in terms of the unlimited data access to Big Tech corporation, which is sometimes we need to be careful on this when we talk about health data.